Skip to Main Content

Author Details

Jenny Lester
David Geffen School of Medicine, University of California at Los Angeles
2012
98
34
PMIDPaper TitleJournal TitlePublished Year
36572991CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.Cancer2023
36948887p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.J Pathol Clin Res2023
36401943Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery.Gynecol Oncol2023
34173196Challenges and Opportunities in Engaging Primary Care Providers in BRCA Testing: Results from the BFOR Study.J Gen Intern Med2022
35454861CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer-A Multicenter Analysis.Cancers (Basel)2022
35816189Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes.Clin Cancer Res2022
35387127Focal Serous Tubal Intra-Epithelial Carcinoma Lesions Are Associated With Global Changes in the Fallopian Tube Epithelia and Stroma.Front Oncol2022
36497028Dynamic Changes in the Extracellular Matrix in Primary, Metastatic, and Recurrent Ovarian Cancers.Cells2022
35883104DNA methylation and transcriptomic features are preserved throughout disease recurrence and chemoresistance in high grade serous ovarian cancers.J Exp Clin Cancer Res2022
36222710Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes.Clin Cancer Res2022
34906490Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study.Genet Med2022
34697060DNA Methylation Profiles of Ovarian Clear Cell Carcinoma.Cancer Epidemiol Biomarkers Prev2022
34782936MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.Virchows Arch2022
32546565Population-based targeted sequencing of 54 candidate genes identifies <i>PALB2</i> as a susceptibility gene for high-grade serous ovarian cancer.J Med Genet2021
33990587Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.Nat Commun2021
34162658Identification of a Locus Near <i>ULK1</i> Associated With Progression-Free Survival in Ovarian Cancer.Cancer Epidemiol Biomarkers Prev2021
32473302Prognostic gene expression signature for high-grade serous ovarian cancer.Ann Oncol2020
33350669Short-term impact of surgically induced menopause on cognitive function and wellbeing in women at high risk for ovarian cancer following risk-reducing bilateral salpingo-oophorectomy.Menopause2020
32807084Comparison of up-front cash cards and checks as incentives for participation in a clinician survey: a study within a trial.BMC Med Res Methodol2020
3297048321 Code of Federal Regulations Part 11-Compliant Digital Signature Solution for Cancer Clinical Trials: A Single-Institution Feasibility Study.JCO Clin Cancer Inform2020
32766252Are Epithelial Ovarian Cancers of the Mesenchymal Subtype Actually Intraperitoneal Metastases to the Ovary?Front Cell Dev Biol2020
32555365Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.Br J Cancer2020
32554541Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).Clin Cancer Res2020
30563893Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer.Cancer Res2019
31213659Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers.Br J Cancer2019
31548585Publisher Correction: Shared heritability and functional enrichment across six solid cancers.Nat Commun2019
30683880Shared heritability and functional enrichment across six solid cancers.Nat Commun2019
30312457Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study.J Natl Cancer Inst2019
29339537<i>STAT3/PIAS3</i> Levels Serve as "Early Signature" Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube.Cancer Res2018
30134598rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology.Int J Mol Sci2018
30062862Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.J Pathol Clin Res2018
29979793Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility.PLoS One2018
29555990Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study.Br J Cancer2018
29502561MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.Mayo Clin Proc2018
29446198Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations.Hum Mutat2018
29738525Optimizing exosomal RNA isolation for RNA-Seq analyses of archival sera specimens.PLoS One2018
29288681Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics.J Control Release2018
27677730No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival.Cancer Epidemiol Biomarkers Prev2017
28346442Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.Nat Genet2017
29029385Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci.Oncotarget2017
29049607Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.JAMA Oncol2017
28881617Germline whole exome sequencing and large-scale replication identifies <i>FANCM</i> as a likely high grade serous ovarian cancer susceptibility gene.Oncotarget2017
28527672Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach.Gynecol Oncol2017
27796716Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3.Breast Cancer Res Treat2017
25940428No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.Gynecol Oncol2016
27836010Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women.Breast Cancer Res2016
27601076Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.Nat Commun2016
27623252Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers.Gynecol Oncol2016
27595995PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.J Med Genet2016
27911851Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration.Oncotarget2016
  • 1 - 50 of 98

Recommended Authors

Pier Selenica
Memorial Sloan Kettering Cancer Center
Career Start Year 2017
Number of shared co-authors 12
Lauren C Peres
H. Lee Moffit Cancer Center and Research Institute
Career Start Year 2016
Number of shared co-authors 48
Padma S Rajagopal
National Cancer Institute, National Institutes of Health
Career Start Year 2014
Number of shared co-authors 0
Arnaud Da Cruz Paula
Memorial Sloan Kettering Cancer Center
Career Start Year 2014
Number of shared co-authors 3
Mollie E Barnard
Boston University Chobanian & Avedisian School of Medicine
Career Start Year 2011
Number of shared co-authors 15
Yuexin Liu
The University of Texas MD Anderson Cancer Center
Career Start Year 2011
Number of shared co-authors 13
Guanglong Jiang
Indiana University School of Medicine
Career Start Year 2011
Number of shared co-authors 0
Eloise Chapman-Davis
Weill Cornell Medical College
Career Start Year 2009
Number of shared co-authors 0
Divya Gupta
Emory University School of Medicine
Career Start Year 2006
Number of shared co-authors 2
Nicola Waddell
QIMR Berghofer Medical Research Institute
Career Start Year 2006
Number of shared co-authors 63
Markus Riester
Novartis Institutes for BioMedical Research
Career Start Year 2005
Number of shared co-authors 3
Andrew H Beck
Beth Israel Deaconess Medical Center, Harvard Medical School
Career Start Year 2004
Number of shared co-authors 55
Dariush Etemadmoghadam
Peter MacCallum Cancer Centre
Career Start Year 2004
Number of shared co-authors 37
Larissa A Korde
Clinical Investigations Branch, National Cancer Institute
Career Start Year 2004
Number of shared co-authors 20
Leah M Prentice
British Columbia Women's Hospital and Health Centre
Career Start Year 2004
Number of shared co-authors 38
Hisani N Horne
National Cancer Institute
Career Start Year 2004
Number of shared co-authors 32
Obi L Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 9
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 2
Maria Del Pilar Estevez Diz
Instituto do Cancer do Estado de Sao Paulo and Universidade de Sao Paulo
Career Start Year 2002
Number of shared co-authors 1
Michael Slifker
Fox Chase Cancer Center
Career Start Year 2002
Number of shared co-authors 1
Siddhartha Deb
Olivia Newton-John Cancer Research Institute
Career Start Year 2002
Number of shared co-authors 4
Blaise A Clarke
University of Toronto.
Career Start Year 2001
Number of shared co-authors 55
Saravut J Weroha
Mayo Clinic
Career Start Year 2001
Number of shared co-authors 22
Richard B Schwab
Department of Medicine and Moores Cancer Center, University of California San Diego
Career Start Year 2000
Number of shared co-authors 3
Steve E Kalloger
University of British Columbia
Career Start Year 2000
Number of shared co-authors 31
Susan C Modesitt
University of Virginia, Emily Couric Clinical Cancer Center
Career Start Year 1998
Number of shared co-authors 4
Ingrid Hedenfalk
Lund University and Skane University Hospital
Career Start Year 1997
Number of shared co-authors 12
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 7
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Career Start Year 1992
Number of shared co-authors 90
Patricia A Shaw
Princess Margaret Cancer Centre, University Avenue
Career Start Year 1990
Number of shared co-authors 48

Collaborators

Beth Y Karlan
David Geffen School of Medicine, University of California los angeles
Co-authored papers 96
Susan J Ramus
School of Clinical Medicine, University of NSW Sydney, Lowy Cancer Research Centre
Co-authored papers 54
Paul D P Pharoah
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 54
Ellen L Goode
Mayo Clinic College of Medicine
Co-authored papers 53
Jacek Gronwald
International Hereditary Cancer Center, Pomeranian Medical University
Co-authored papers 51
Jan Lubinski
Pomeranian Medical University
Co-authored papers 51
Georgia Chenevix-Trench
QIMR Berghofer Medical Research Institute
Co-authored papers 51
Peter A Fasching
Otto-Friedrich-University Bamberg
Co-authored papers 49
Simon A Gayther
Cedars-Sinai Medical Center
Co-authored papers 48
Marc T Goodman
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 45
Andrew Berchuck
Duke School of Medicine
Co-authored papers 44
Joellen M Schildkraut
Rollins School of Public Health, Emory University
Co-authored papers 41
Diether Lambrechts
Co-authored papers 41
Jenny Chang-Claude
German Cancer Research Center (DKFZ)
Co-authored papers 40
Usha Menon
College of Nursing, University of South Florida
Co-authored papers 40
Alice S Whittemore
Co-authored papers 39
Ian G Campbell
Co-authored papers 39
Weiva Sieh
Co-authored papers 38
Anna H Wu
University of Southern California
Co-authored papers 38
Aleksandra Gentry-Maharaj
UCL EGA Institute for Women's Health, University College London
Co-authored papers 37
Tanja Pejovic
Oregon Health & Science University
Co-authored papers 37
Cezary Cybulski
International Hereditary Cancer Center, Pomeranian Medical University
Co-authored papers 36
Sandra Orsulic
David Geffen School of Medicine, University of California at Los Angeles
Co-authored papers 36
Douglas A Levine
Perlmutter Cancer Center
Co-authored papers 36
Honglin Song
University of Cambridge
Co-authored papers 36
Mary Anne Rossing
Fred Hutchinson Cancer Research Center
Co-authored papers 35
Celeste Leigh Pearce
University of Michigan School of Public Health ann arbor
Co-authored papers 35
Javier Ben??tez
Instituto de Salud Carlos III
Co-authored papers 34
Douglas F Easton
University of Cambridge
Co-authored papers 34
Hoda Anton-Culver
University of California irvine
Co-authored papers 34
Release 1.2